Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Int J Oncol
    April 2024
  1. XIE L, Xie D, Du Z, Xue S, et al
    A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).
    Int J Oncol. 2024;64:38.
    >> Share

    March 2024
  2. LI S, Li Z, Huang L, Geng Z, et al
    SLCO4A1, as a novel prognostic biomarker of non?small cell lung cancer, promotes cell proliferation and migration.
    Int J Oncol. 2024;64:30.
    >> Share

  3. WU G, Wang D, Xiong F, Wang Q, et al
    The emerging roles of CEACAM6 in human cancer (Review).
    Int J Oncol. 2024;64:27.
    >> Share

    December 2023
  4. SHIE WY, Chu PH, Kuo MY, Chen HW, et al
    Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry.
    Int J Oncol. 2023;63:136.
    >> Share

    November 2023
  5. HU X, Ren J, Xue Q, Luan R, et al
    Anti?PD?1/PD?L1 and anti?CTLA?4 associated checkpoint inhibitor pneumonitis in non?small cell lung cancer: Occurrence, pathogenesis and risk factors (Review).
    Int J Oncol. 2023;63:122.
    >> Share

    August 2023
  6. JIN Y, Zhang Y, Huang A, Chen Y, et al
    Overexpression of SERPINA3 suppresses tumor progression by modulating SPOP/NF‑kappaB in lung cancer.
    Int J Oncol. 2023;63:96.
    >> Share

    May 2023
  7. XUE T, Chen Y, Xu J, Du W, et al
    Cyclovirobuxine D inhibits growth and progression of non‑small cell lung cancer cells by suppressing the KIF11‑CDC25C‑CDK1‑CyclinB1 G(2)/M phase transition regulatory network and the NFkappaB/JNK signaling pathway.
    Int J Oncol. 2023;62:57.
    >> Share

  8. LI H, Feng Z, Wu W, Li J, et al
    [Retracted] SIRT3 regulates cell proliferation and apoptosis related to energy metabolism in non‑small cell lung cancer cells through deacetylation of NMNAT2.
    Int J Oncol. 2023;62:60.
    >> Share

  9. TIAN Z, Li J, Ma R, Li T, et al
    Targeting neddylation as a novel approach to lung cancer treatment (Review).
    Int J Oncol. 2023;62:65.
    >> Share

    February 2023
  10. WANG F, Yu C, Chen L, Xu S, et al
    Landscape of circular RNAs in different types of lung cancer and an emerging role in therapeutic resistance (Review).
    Int J Oncol. 2023;62:21.
    >> Share

  11. WANG Q, Zeng A, Zhu M, Song L, et al
    Dual inhibition of EGFR‑VEGF: An effective approach to the treatment of advanced non‑small cell lung cancer with EGFR mutation (Review).
    Int J Oncol. 2023;62:26.
    >> Share

    January 2023
  12. ZHANG W, Cai X, Yu J, Lu X, et al
    [Retracted] Exosome‑mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non‑small cell lung cancer.
    Int J Oncol. 2023;62:10.
    >> Share

  13. YANG Y, Zheng X, Ni P, Li D, et al
    Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLC.
    Int J Oncol. 2023;62:12.
    >> Share

    December 2022
  14. TANG Q, Li M, Chen L, Bi F, et al
    [Corrigendum] miR200b/c targets the expression of RhoE and inhibits the proliferation and invasion of nonsmall cell lung cancer cells.
    Int J Oncol. 2022;61.
    >> Share

  15. GUO H, Zhang X, Xie S, Chen T, et al
    Gefitinib enhances the antitumor immune response against EGFRmutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
    Int J Oncol. 2022;61.
    >> Share

  16. CAO H, Wang Z, Wang Y, Ye L, et al
    PPP1R14D promotes the proliferation, migration and invasion of lung adenocarcinoma via the PKCalpha/BRAF/MEK/ERK signaling pathway.
    Int J Oncol. 2022;61.
    >> Share

  17. ORTEGA MA, Navarro F, Pekarek L, Fraile-Martinez O, et al
    Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review).
    Int J Oncol. 2022;61.
    >> Share

  18. LIU X, Hai Y, Dong J, Xu L, et al
    Realgarinduced KRAS mutation lung cancer cell death via KRAS/Raf/MAPK mediates ferroptosis.
    Int J Oncol. 2022;61.
    >> Share

  19. SU XE, Hong WP, He HF, Lin S, et al
    Recent advances in postoperative pulmonary rehabilitation of patients with nonsmall cell lung cancer (Review).
    Int J Oncol. 2022;61.
    >> Share

    September 2022
  20. ZHANG J, Li J, Li S, Zhou C, et al
    [Retracted] miR802 inhibits the aggressive behaviors of nonsmall cell lung cancer cells by directly targeting FGFR1.
    Int J Oncol. 2022;61.
    >> Share

  21. NIAN R, Jiang H, Zhao J, Hou W, et al
    Differences in actionable genomic alterations between brain metastases and nonbrain metastases in patients with nonsmall cell lung cancer.
    Int J Oncol. 2022;61.
    >> Share

    July 2022
  22. GENG F, Yang W, Song D, Hou H, et al
    MDIG, a 2oxoglutaratedependent oxygenase, acts as an oncogene and predicts the prognosis of multiple types of cancer.
    Int J Oncol. 2022;61.
    >> Share

  23. ZHOU J, Xu Y, Wang G, Mei T, et al
    The TLR7/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer.
    Int J Oncol. 2022;61.
    >> Share

    April 2022
  24. WANG L, Xu X, Shang B, Sun J, et al
    High farnesoid X receptor expression predicts favorable clinical outcomes in PDL1(low/negative) nonsmall cell lung cancer patients receiving antiPD1based chemoimmunotherapy.
    Int J Oncol. 2022;60.
    >> Share

  25. SCHNEIDER MA, Richtmann S, Grunding AR, Wrenger S, et al
    Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma.
    Int J Oncol. 2022;60.
    >> Share

    March 2022
  26. MADSEN KL, Langkjaer N, Gerke O, Hoilund-Carlsen PF, et al
    Establishment of patientderived lung tumorspheres and their response to internal irradiation by Auger electrons.
    Int J Oncol. 2022;60.
    >> Share

    February 2022
  27. CHEN MZ, Su LY, Ko PH, Hsu MH, et al
    Extracellular domain of semaphorin 5A serves a tumorsuppressing role by activating interferon signaling pathways in lung adenocarcinoma cells.
    Int J Oncol. 2022;60.
    >> Share

    January 2022
  28. LEE A, Jin HO, Masudul Haque M, Kim HY, et al
    Synergism of a novel MCL1 downregulator, acriflavine, with navitoclax (ABT263) in triplenegative breast cancer, lung adenocarcinoma and glioblastoma multiforme.
    Int J Oncol. 2022;60.
    >> Share

    November 2021
  29. JIANG G, Yu H, Li Z, Zhang F, et al
    lncRNA cytoskeleton regulator reduces nonsmall cell lung cancer radiosensitivity by downregulating miRNA206 and activating prothymosin alpha.
    Int J Oncol. 2021;59.
    >> Share

  30. HE J, Huang Z, Han L, Gong Y, et al
    Mechanisms and management of 3rdgeneration EGFRTKI resistance in advanced nonsmall cell lung cancer (Review).
    Int J Oncol. 2021;59.
    >> Share

  31. HE B, Wu C, Sun W, Qiu Y, et al
    miR383 increases the cisplatin sensitivity of lung adenocarcinoma cells through inhibition of the RBM24mediated NFkappaB signaling pathway.
    Int J Oncol. 2021;59.
    >> Share

    October 2021
  32. KAHM YJ, Kim RK, Jung U, Kim IG, et al
    Epithelial membrane protein 3 regulates lung cancer stem cells via the TGFbeta signaling pathway.
    Int J Oncol. 2021;59.
    >> Share

    September 2021
  33. XIA H, Li Y, Lv X
    [Retracted] MicroRNA107 inhibits tumor growth and metastasis by targeting the BDNFmediated PI3K/AKT pathway in human nonsmall lung cancer.
    Int J Oncol. 2021;59.
    >> Share

    June 2021
  34. WANG D, Wu J, Wang D, Huang X, et al
    Cisplatin enhances protein OGlcNAcylation by altering the activity of OGT, OGA and AMPK in human nonsmall cell lung cancer cells.
    Int J Oncol. 2021;58.
    >> Share

  35. MORELLI AP, Tortelli TC Jr, Pavan ICB, Silva FR, et al
    Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways.
    Int J Oncol. 2021;58.
    >> Share

    May 2021
  36. WANG J, Liang J, Li H, Han J, et al
    Oncogenic role of abnormal spindlelike microcephalyassociated protein in lung adenocarcinoma.
    Int J Oncol. 2021;58.
    >> Share

    April 2021
  37. YAMAMOTO S, Lee S, Ariyasu T, Endo S, et al
    Ingredients such as trehalose and hesperidin taken as supplements or foods reverse alterations in human T cells, reducing asbestos exposure-induced antitumor immunity.
    Int J Oncol. 2021;58.
    >> Share

    February 2021
  38. VAID AK, Gupta A, Momi G
    Overall survival in stage IV EGFR mutationpositive NSCLC: Comparing first, second and thirdgeneration EGFRTKIs (Review).
    Int J Oncol. 2021;58:171-184.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016